Fred Henretig , MD
Site investigator, Philadelphia Clinical Center — Children's Hospital of Philadelphia
- Site
- Philadelphia
- Affiliation
- Children's Hospital of Philadelphia
- TLC era
- 1990s
- Tags
- Co-InvestigatorPediatric ToxicologyEmergency Medicine
Pediatric toxicologist and emergency medicine specialist at Children's Hospital of Philadelphia. Involved in patient enrollment and clinical management at the Philadelphia TLC site.
Author of an invited 2001 commentary in J Toxicol Clin Toxicol evaluating TLC's null result. Originated as impromptu remarks at the 21st EAPCCT meeting in Barcelona (May 2001). The commentary discloses his TLC investigator role and potential bias, then endorses the trial's methodology and null finding as definitive — and extends this skepticism to asymptomatic children above 44 µg/dL.
Site investigator at the Philadelphia clinical center.
Authored a key 2001 commentary defending TLC's aggressive dosing (BSA-based dosing yielding ~50% higher daily doses, 7-day induction, 26-day courses) as a standard rebuttal to critics who argued the trial undertreated participants.
His commentary does not engage the blood-vs-brain compartment distinction (succimer reduces blood Pb ~50% but brain Pb only 20–25%), nor whether the short-lived BLL difference was mechanistically sufficient to protect development.
“Clinicians treating asymptomatic children above 44 µg/dL really have little hard evidence to support that either.”